Zhejiang Tianyu Pharmaceutical (300702.SZ) subsidiary receives drug registration certificate for Ibrutinib Capsules
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Ibrutinib Capsules approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm's macroglobulinemia, and others. According to statistics, the sales of Ibrutinib Capsules in domestic sample hospitals and urban brick-and-mortar pharmacies in 2025 were approximately RMB399 million (data sourced from Menet).
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Ibrutinib Capsules approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm's macroglobulinemia, and other conditions. According to statistics, the sales of Ibrutinib Capsules in domestic sample hospitals and urban brick-and-mortar pharmacies in 2025 amounted to approximately RMB399 million (data sourced from Menet).
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






